fludarabine and nutlin-3a

fludarabine has been researched along with nutlin-3a in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andreeff, M; Kojima, K; Konopleva, M; McQueen, T; O'Brien, S; Plunkett, W1
Barbarotto, E; Celeghini, C; Corallini, F; Fadda, R; Grill, V; Mischiati, C; Rimondi, E; Vaccarezza, M1
Fan, L; Fang, C; Li, JY; Liu, L; Xu, W; Yang, S; Zhang, LN; Zou, ZJ1
Fan, L; Li, JY; Liu, L; Wang, DM; Xu, W; Yang, S; Zhang, LN; Zou, ZJ1
Derks, IA; Eldering, E; Geisler, CH; Hüllein, J; Jethwa, A; Kater, AP; Lodén, M; Malcikova, J; Moerland, PD; Monsuur, H; Navrkalova, V; Oldreive, C; Pospisilova, S; Skowronska, A; Stankovic, T; Te Raa, GD; Trbusek, M; van Laar, J; van Oers, MH; Zenz, T1

Other Studies

5 other study(ies) available for fludarabine and nutlin-3a

ArticleYear
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Blood, 2006, Aug-01, Volume: 108, Issue:3

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cells, Cultured; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Transcription, Genetic; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine

2006
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
    Journal of cellular biochemistry, 2008, May-15, Volume: 104, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Blast Crisis; Cell Cycle; Cell Line, Tumor; Chlorambucil; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperazines; Proto-Oncogene Proteins c-mdm2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Vidarabine

2008
S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
    Cancer science, 2012, Volume: 103, Issue:12

    Topics: Aged; Animals; Antineoplastic Agents; Cell Cycle Proteins; Female; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Middle Aged; Nuclear Proteins; Piperazines; Prognosis; Protein Splicing; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Tumor Suppressor Protein p53; Vidarabine

2012
Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.
    Cancer biology & therapy, 2012, Volume: 13, Issue:14

    Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomal Proteins, Non-Histone; Female; Humans; Imidazoles; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleoproteins; Oncogene Proteins; Piperazines; Poly-ADP-Ribose Binding Proteins; Prognosis; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase

2012
The impact of SF3B1 mutations in CLL on the DNA-damage response.
    Leukemia, 2015, Volume: 29, Issue:5

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cohort Studies; DNA Damage; DNA Mutational Analysis; Doxorubicin; Flow Cytometry; Gene Deletion; Gene Expression Regulation, Leukemic; Genome, Human; Histones; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Phosphoproteins; Piperazines; Prognosis; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Tumor Suppressor Protein p53; Vidarabine

2015